Free Newsletter
Allergan, FDA fight eyelash-mad copycats
It looks like a drug, it acts like a drug, but if comes in a cosmetics tube instead of an eyedropper, is it still a drug?
Call it the case of the thicker-lashed glaucoma patient. Lumigan, a glaucoma remedy sold by Allergan, has the unusual added benefit of promoting eyelash growth. Some eye docs are prescribing it not only to glaucoma patients, but off-label for cosmetics use. Meanwhile, an entrepreneurial cosmetics maker allegedly used similar ingredients in a mascara-like package. The FDA seized raided the company and seized boxes of the product on Friday, calling it a "mislabeled drug."
Meanwhile, Allergan itself is rumored to be testing Lumigan for cosmetic use. And it has sued seven cosmetics companies for patent infringement. Of course, the company has plenty of experience pushing medical remedies into the profitable cosmeceuticals realm. Remember Botox?
- check out the Wall Street Journal article
Related Articles:
Allergan wins FDA OK for new therapy. Report
Allergan injects $370M into Esprit buyout. Report
Allergan buying Groupe Corneal. Report
Comments
Revitalash had to withdraw their original formula, which promoted eyelash growth. The New Revitalash does not work. Eyelash Products and its Reviews reveal that Revitalash is being sued and it's product is full of air.
Revitalash new formula still causes decreased vision and darkening of the IRIS. Beware, if you have blue or hazel eyes. To be fare, any product that has prostoglandin, will cause decreaed vision and darkening of the iris.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: